365 related articles for article (PubMed ID: 25179757)
1. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation.
Weber T; Wickenhauser C; Monecke A; Gläser C; Stadler M; Desole M; Ligeti K; Behrmann C; Müller-Tidow C; Müller LP
Transpl Infect Dis; 2014 Dec; 16(6):988-92. PubMed ID: 25179757
[TBL] [Abstract][Full Text] [Related]
2. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
[TBL] [Abstract][Full Text] [Related]
3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
4. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Presentation of Hemophagocytic Lymphohistiocytosis and Posttransplant Lymphoproliferative Disease-Like Lymphoma in a Mildly Immunosuppressed Leukemia Patient: An Unusual Association.
Sinno MG; Rosen D; Wittler R
Pediatr Blood Cancer; 2016 Aug; 63(8):1474-6. PubMed ID: 27148941
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
10. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
11. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
14. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
15. Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: A dreaded complication in a post-liver transplant child.
Jha B; Mohan N; Gajendra S; Sachdev R; Goel S; Sahni T; Raina V; Soin A
Pediatr Transplant; 2015 Nov; 19(7):E177-80. PubMed ID: 26184957
[TBL] [Abstract][Full Text] [Related]
16. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC
Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
[TBL] [Abstract][Full Text] [Related]
17. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
Balamuth NJ; Nichols KE; Paessler M; Teachey DT
J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
[TBL] [Abstract][Full Text] [Related]
18. Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virus-associated T-cell lymphoproliferative disorder.
Nawathe PA; Ravindranath TM; Satwani P; Baird JS
Pediatr Crit Care Med; 2013 May; 14(4):e176-81. PubMed ID: 23439459
[TBL] [Abstract][Full Text] [Related]
19. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
20. TEN-like eruption in setting of EBV positive T-cell lymphoproliferative disease with HLH, in a child.
Sharma N; Clark J; Pham H; Efron D; MacGregor D; O'Keefe R; Orchard D
Australas J Dermatol; 2014 Aug; 55(3):e44-7. PubMed ID: 23573996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
